$SNWV
SANUWAVE Health, Inc.

2016 Q3 Form 10-Q Financial Statement

#000143774916041409 Filed on November 08, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2015 Q4 2015 Q3
Revenue $255.7K $143.6K
YoY Change 78.02% -36.87%
Cost Of Revenue $98.68K $38.75K
YoY Change 154.64% -43.08%
Gross Profit $157.0K $104.9K
YoY Change 49.71% -34.23%
Gross Profit Margin 61.4% 73.01%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $266.5K $569.1K
YoY Change -53.18% -19.65%
% of Gross Profit 169.76% 542.79%
Depreciation & Amortization $1.554K $80.00K $926.00
YoY Change 67.82% 0.0% -75.8%
% of Gross Profit 0.99% 0.88%
Operating Expenses $990.6K $1.425M
YoY Change -30.51% -9.15%
Operating Profit -$833.6K -$1.321M
YoY Change -36.88% -6.31%
Interest Expense $225.3K $105.8K
YoY Change 112.84% 32.36%
% of Operating Profit
Other Income/Expense, Net -$306.2K $293.7K
YoY Change -204.25% -452.26%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.140M -$1.027M
YoY Change 11.0% -31.22%
Net Earnings / Revenue -445.84% -715.05%
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $500.0K $150.0K $630.0K
YoY Change -20.63% -95.77% -86.57%
Cash & Equivalents $504.4K $152.9K $625.5K
Short-Term Investments
Other Short-Term Assets $120.0K $120.0K $150.0K
YoY Change -20.0% -7.69% -6.25%
Inventory $267.0K $284.9K $291.4K
Prepaid Expenses $123.2K $124.0K $152.3K
Receivables $141.3K $74.45K $32.01K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.036M $636.3K $1.101M
YoY Change -5.92% -84.23% -78.83%
LONG-TERM ASSETS
Property, Plant & Equipment $8.879K $4.228K $5.065K
YoY Change 75.3% -46.07% -49.35%
Goodwill
YoY Change
Intangibles $76.69K $306.8K $383.4K
YoY Change -80.0% -50.0%
Long-Term Investments
YoY Change
Other Assets $13.94K $11.10K $11.16K
YoY Change 24.91% -0.08% 11.6%
Total Long-Term Assets $99.51K $322.1K $399.7K
YoY Change -75.1% -49.07% -43.71%
TOTAL ASSETS
Total Short-Term Assets $1.036M $636.3K $1.101M
Total Long-Term Assets $99.51K $322.1K $399.7K
Total Assets $1.135M $958.4K $1.501M
YoY Change -24.34% -79.46% -74.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $376.1K $509.3K $315.7K
YoY Change 19.15% 119.66% -21.09%
Accrued Expenses $417.2K $359.4K $400.5K
YoY Change 4.18% -2.73% -28.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.392M $1.488M $1.285M
YoY Change 8.33% -76.07% -79.71%
LONG-TERM LIABILITIES
Long-Term Debt $5.360M $5.350M $5.340M
YoY Change 0.37%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $5.360M $5.350M $5.340M
YoY Change 0.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.392M $1.488M $1.285M
Total Long-Term Liabilities $5.360M $5.350M $5.340M
Total Liabilities $6.749M $6.836M $6.627M
YoY Change 1.84% 9.95% 4.69%
SHAREHOLDERS EQUITY
Retained Earnings -$96.98M -$92.99M -$91.89M
YoY Change 5.54% 5.45%
Common Stock $136.7K $87.09M $63.06K
YoY Change 116.72% 143306.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.614M -$5.878M -$5.126M
YoY Change
Total Liabilities & Shareholders Equity $1.135M $958.4K $1.501M
YoY Change -24.34% -79.46% -74.61%

Cashflow Statement

Concept 2016 Q3 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$1.140M -$1.027M
YoY Change 11.0% -31.22%
Depreciation, Depletion And Amortization $1.554K $80.00K $926.00
YoY Change 67.82% 0.0% -75.8%
Cash From Operating Activities -$980.0K -$460.0K -$1.090M
YoY Change -10.09% -59.65% -24.83%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $100.0K
YoY Change -100.0%
Cash From Investing Activities -$10.00K $0.00 $100.0K
YoY Change -110.0% -1100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.370M 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -980.0K -460.0K -1.090M
Cash From Investing Activities -10.00K 0.000 100.0K
Cash From Financing Activities 1.370M 0.000 0.000
Net Change In Cash 380.0K -460.0K -990.0K
YoY Change -138.38% -59.65% -32.19%
FREE CASH FLOW
Cash From Operating Activities -$980.0K -$460.0K -$1.090M
Capital Expenditures -$10.00K $0.00 $0.00
Free Cash Flow -$970.0K -$460.0K -$1.090M
YoY Change -11.01% -59.65% -24.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 snwv Accrued Audit And Tax Preparation
AccruedAuditAndTaxPreparation
70128
CY2015Q4 snwv Accrued Audit And Tax Preparation
AccruedAuditAndTaxPreparation
93500
CY2016Q3 snwv Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
13650
CY2015Q4 snwv Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
22777
CY2016Q3 snwv Accrued Directors And Advisers Fees
AccruedDirectorsAndAdvisersFees
61000
CY2015Q4 snwv Accrued Directors And Advisers Fees
AccruedDirectorsAndAdvisersFees
CY2016Q3 snwv Accrued Executive Severance
AccruedExecutiveSeverance
100000
CY2015Q4 snwv Accrued Executive Severance
AccruedExecutiveSeverance
100000
CY2016Q3 snwv Accrued Inventory Expense
AccruedInventoryExpense
27948
CY2015Q4 snwv Accrued Inventory Expense
AccruedInventoryExpense
CY2016Q3 snwv Accrued Outside Services Current
AccruedOutsideServicesCurrent
CY2015Q4 snwv Accrued Outside Services Current
AccruedOutsideServicesCurrent
58813
CY2016Q3 snwv Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
19033
CY2015Q4 snwv Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
CY2016Q1 snwv Class Of Warrant Or Right Change In Fair Value
ClassOfWarrantOrRightChangeInFairValue
-90722
CY2016Q2 snwv Class Of Warrant Or Right Change In Fair Value
ClassOfWarrantOrRightChangeInFairValue
-28250
CY2016Q3 snwv Class Of Warrant Or Right Change In Fair Value
ClassOfWarrantOrRightChangeInFairValue
115200
snwv Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
6985000
snwv Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
-3576737
CY2016Q3 snwv Class Of Warrant Or Right Gain Loss From Cashless Exercise During Period
ClassOfWarrantOrRightGainLossFromCashlessExerciseDuringPeriod
-87800
snwv Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
74633960
CY2016Q1 snwv Class Of Warrant Or Right Value Issued During Period
ClassOfWarrantOrRightValueIssuedDuringPeriod
75422
CY2016Q2 snwv Class Of Warrant Or Right Value Issued During Period
ClassOfWarrantOrRightValueIssuedDuringPeriod
25350
CY2016Q3 snwv Class Of Warrant Or Right Value Issued During Period
ClassOfWarrantOrRightValueIssuedDuringPeriod
snwv Class Of Warrant Or Rights Converted During The Period
ClassOfWarrantOrRightsConvertedDuringThePeriod
23701427
CY2016Q3 snwv Gain Loss On Warrant Valuation Adjustment And Conversion
GainLossOnWarrantValuationAdjustmentAndConversion
-43536
CY2015Q3 snwv Gain Loss On Warrant Valuation Adjustment And Conversion
GainLossOnWarrantValuationAdjustmentAndConversion
302300
snwv Gain Loss On Warrant Valuation Adjustment And Conversion
GainLossOnWarrantValuationAdjustmentAndConversion
-812983
snwv Gain Loss On Warrant Valuation Adjustment And Conversion
GainLossOnWarrantValuationAdjustmentAndConversion
-70985
CY2016Q3 snwv Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
CY2015Q4 snwv Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
239803
CY2016Q1 snwv Share Based Compensation Arrangement By Share Based Payment Award Options Cancel In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelInPeriod
CY2016Q3 snwv Share Based Compensation Arrangement By Share Based Payment Award Options Cancel In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelInPeriod
CY2016Q1 snwv Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePricePerShare
CY2016Q3 snwv Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePricePerShare
snwv Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0
snwv Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7076
CY2015Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
114522
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
CY2016Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
26974
CY2016Q3 us-gaap Assets
Assets
1135428
CY2015Q4 us-gaap Assets
Assets
958361
CY2016Q3 us-gaap Assets Current
AssetsCurrent
1035920
CY2015Q4 us-gaap Assets Current
AssetsCurrent
636280
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
376093
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
509266
CY2016Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
141297
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
74454
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
417243
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
359374
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
40000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
76500
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-38142
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33162
CY2016Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
91268738
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87086677
CY2016Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
24339
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
8963
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
18548
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
6658
CY2015Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
CY2015Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
76689
CY2016Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
76689
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
230067
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
230068
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
92046867
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
45609516
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
504404
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
152930
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3547071
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
625450
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
351474
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2921621
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
38302686
CY2016Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
78673482
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
136659125
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63056519
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
136659125
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63056519
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
136659
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
63057
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1142078
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1027189
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3991489
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3721323
CY2016Q3 us-gaap Cost Of Revenue
CostOfRevenue
98678
CY2015Q3 us-gaap Cost Of Revenue
CostOfRevenue
38752
us-gaap Cost Of Revenue
CostOfRevenue
249847
us-gaap Cost Of Revenue
CostOfRevenue
173349
CY2016Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
26606
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
32244
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
us-gaap Depreciation
Depreciation
3227
us-gaap Depreciation
Depreciation
2775
CY2016Q3 us-gaap Depreciation
Depreciation
1554
CY2015Q3 us-gaap Depreciation
Depreciation
926
CY2016Q3 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
147300
CY2015Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
138100
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2016Q3 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-4980
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-13831
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
451007
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
241542
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
70985
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
812982
CY2016Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3425446
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3195379
CY2016Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3502135
CY2015Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3502135
CY2016Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
76689
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
306756
CY2016Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3367
CY2015Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2739
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9215
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-15458
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
100000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2016Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2015Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2015Q3 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
100000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
100000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
645863
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
778679
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1734891
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1981541
CY2016Q3 us-gaap Gross Profit
GrossProfit
156974
CY2015Q3 us-gaap Gross Profit
GrossProfit
104853
us-gaap Gross Profit
GrossProfit
478535
us-gaap Gross Profit
GrossProfit
420691
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-133173
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
83811
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
82219
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-63582
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
60369
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
31032
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
209465
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
198581
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-239803
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
18259
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-17922
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19483
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-32271
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2843
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
54
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-755
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
23711
CY2016Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
76689
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
306756
CY2016Q3 us-gaap Interest Expense
InterestExpense
225252
CY2015Q3 us-gaap Interest Expense
InterestExpense
105830
us-gaap Interest Expense
InterestExpense
489996
us-gaap Interest Expense
InterestExpense
266810
us-gaap Interest Paid
InterestPaid
630549
us-gaap Interest Paid
InterestPaid
242904
CY2016Q3 us-gaap Inventory Net
InventoryNet
266986
CY2015Q4 us-gaap Inventory Net
InventoryNet
284908
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
43540
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
CY2016Q3 us-gaap Liabilities
Liabilities
6749089
CY2015Q4 us-gaap Liabilities
Liabilities
6836197
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1135428
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
958361
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1391643
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1488085
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Nature of the Business</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">SANUWAVE Health, Inc. and subsidiaries (the &#x201c;Company&#x201d;) is an acoustic pressure shock wave technology company using a patented system of noninvasive, high-energy, acoustic pressure shock waves for indications such as regenerative medicine and other applications. The Company&#x2019;s initial focus is regenerative medicine &#x2013; utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. The Company&#x2019;s lead regenerative product in the United States is the dermaPACE<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom:.33em;">&reg;</div> device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies. A <div style="display: inline; font-style: italic;">de novo</div> petition was sent to FDA on July 23, 2016 requesting Agency review and classification of the dermaPACE device for treating diabetic foot ulcers as a Class II device, for possible approval in late 2016 or early 2017. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#x2019;s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body&#x2019;s normal healing processes and regeneration. The Company intends to apply its Pulsed Acoustic Cellular Expression (PACE<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom:.33em;">&reg;</div>) technology in wound healing, orthopedic, plastic/cosmetic and cardiac/endovascular conditions. Revenues are from sales of the European Conformity Marking (&#x201c;CE Mark&#x201d;) devices and accessories in Europe, Canada, Asia and Asia/Pacific. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In addition to healthcare uses, our high-energy, acoustic pressure shock waves, due to their powerful pressure gradients and localized cavitational effects, may have applications in secondary and tertiary oil exploitation, for cleaning industrial waters, for sterilizing food liquids and finally for maintenance of industrial installations by disrupting biofilms formation. Our business approach will be through licensing and/or partnership opportunities.</div></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3072305
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6878
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2708973
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3007790
us-gaap Net Income Loss
NetIncomeLoss
-3986509
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-4810285
us-gaap Net Income Loss
NetIncomeLoss
-3707492
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-1139810
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-1026844
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-306205
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
293731
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1444264
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-253253
CY2016Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
5357446
CY2015Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
5348112
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
990579
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
1425428
us-gaap Operating Expenses
OperatingExpenses
3020780
us-gaap Operating Expenses
OperatingExpenses
3874930
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-833605
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1320575
us-gaap Operating Income Loss
OperatingIncomeLoss
-2542245
us-gaap Operating Income Loss
OperatingIncomeLoss
-3454239
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
47108
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
32836
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
130083
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
104747
CY2016Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
70096802
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
26634
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7784
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13940
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11097
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2268
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-345
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4980
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-13831
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7878
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
569134
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1052595
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1660546
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96980916
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92994408
CY2016Q3 us-gaap Revenues
Revenues
255652
CY2015Q3 us-gaap Revenues
Revenues
143605
us-gaap Revenues
Revenues
728382
CY2016Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
123233
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
123988
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1528200
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1596855
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
100000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
32000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8879
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
15376
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-9186
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
266473
us-gaap Revenues
Revenues
594040
us-gaap Share Based Compensation
ShareBasedCompensation
116550
us-gaap Share Based Compensation
ShareBasedCompensation
146385
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0241
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.4
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.361
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
13273385
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.43
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3300000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10073385
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10073385
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13373385
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13373385
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.62
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.55
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.55
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.43
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2016Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.04
CY2016Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2016Q3 us-gaap Share Price
SharePrice
0.11
CY2016Q3 us-gaap Share Price
SharePrice
0.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y182D
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
175002
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
175002
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
100000
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
100000
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.36
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.36
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.21
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.21
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
3375002
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.05
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2016Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
435392
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
-5613661
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-5877836
CY2015Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
138100
CY2016Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
122800
CY2016Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
119900
CY2016Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
147300
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
115528604
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63056519
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
97798261
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63014763

Files In Submission

Name View Source Status
0001437749-16-041409-index-headers.html Edgar Link pending
0001437749-16-041409-index.html Edgar Link pending
0001437749-16-041409.txt Edgar Link pending
0001437749-16-041409-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snwv-20160930.xml Edgar Link completed
snwv-20160930.xsd Edgar Link pending
snwv-20160930_cal.xml Edgar Link unprocessable
snwv-20160930_def.xml Edgar Link unprocessable
snwv-20160930_lab.xml Edgar Link unprocessable
snwv-20160930_pre.xml Edgar Link unprocessable
snwv20160901_10q.htm Edgar Link pending